An interventional study of MDA and Placebo in Healthy, sponsored by California Pacific Medical Center Research Institute. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-05-31.
Sponsored by California Pacific Medical Center Research Institute · Not applicable, Interventional, and Basic science
The purpose of this study is to investigate the pharmacological and cognitive effects of MDA in healthy humans.
California Pacific Medical Center Research Institute is the lead sponsor of 39 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
FOR MORE DETAILS CONTACT THE RESEARCH CLINIC.
Drug: MDA · Drug: Placebo
subjects will receive a single oral dose of MDA 98mg/70kg body weight
Subjects will receive a single oral dose of placebo
MDA will be metabolized to hydroxyamphetamine (HMA) and dihydroxyamphetamine (DHA) and will produce dose-dependent increases in neuroendocrine measures.
Time frame: 0-48 hours post dose
MDA will produce dose-dependent increases in self-report entactogen-like and stimulant like measures.
Time frame: 0-48 hours post dose
This study is completed, as verified in May 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
California Pacific Medical Center Research Institute